CEPI: Getting more COVID-19 vaccine for the world
Another CEPI partner, Clover Biopharmaceuticals, has become the latest vaccine developer to sign an advance purchase agreement with COVAX to make their COVID-19 vaccine available to populations worldwide.
Under the new agreement between Clover and our COVAX partner, Gavi, up to 414 million doses are set to be made available to participating countries in 2021 and 2022. CEPI’s significant early investments have been critical to the development of Clover’s vaccine candidate, and were directly linked to access commitments which enabled this deal.
Since late Spring, 2020, CEPI has provided up to $328 million to support preclinical and clinical testing of the candidate vaccine, in addition to scaling-up the biotech’s in-house manufacturing capacity. Clover yesterday announced that its pivotal global Phase 2/3 clinical trial—funded by CEPI—is now fully enrolled, and that interim efficacy data is expected in Q3.
COVAX has now distributed over 100 million vaccines since its launch in February this year. Supply of Clover’s vaccine is anticipated to start in the last quarter of the year, pending Emergency Use Licensure from the World Health Organization (WHO).
To learn more visit https://cepi.net/news_cepi/from-lab-to-potential-jab-clovers-covid-19-vaccine-story/
Articles
13Th Edition Of The Edctp Forum To Take Place In Madrid, Spain, From 5 To 9 April 2027
We are delighted to announce that the 13th edition of the EDCTP Forum will be celebrated on 5-9 April 2027, at IFEMA Palacio Municipal in Madrid, Spain.
The event will be co-hosted by the Instituto de Salud Carlos III (ISCIII) under the Spanish Ministry of Science, Innovation and Universities and the Fundación CSAI (FCSAI) under the Ministry of Health, and is co-organised by Global Health EDCTP3 and the EDCTP Association.
Over the past two decades, the biennial European & Developing Countries Clinical Trials Partnership (EDCTP) Forum has evolved to become a cornerstone event for global health research, bringing together leading voices advancing the fight against infectious diseases in sub-Saharan Africa. It showcases the latest scientific breakthroughs, highlights impactful capacity-building efforts, and creates a space for vibrant cross-regional collaboration.
The EDCTP Forum 2027 expects to convene 1,500 participants and stakeholders, from researchers, universities and clinicians to governments, regional bodies, civil society, regulators, and public and private R&D partners, drawing participation primarily from Africa and Europe.
Dr Tuelo Mogashoa Becomes First Tagendi Phd Graduate
Botswana-born scientist Dr Tuelo Mogashoa, a PhD Fellow in the ‘Addressing Gender and Diversity Regional Gaps in Clinical Research Capacity’ (TAGENDI) programme, has successfully defended her PhD in Molecular Biology (Tuberculosis Genomics) at Stellenbosch University. Her virtual oral examination, held on 12 January 2025, marked the culmination of years of research and training.
Her doctoral thesis, titled “Rifampicin- resistant tuberculosis: an emerging threat to human health in Botswana,” addresses one of the most pressing challenges in TB control.
Dr Mogashoa is the first of seven PhD fellows from the inaugural TAGENDI cohort to complete her doctoral studies. The TAGENDI fellowship, implemented under the Trials of Excellence in Southern Africa (TESA) Network, is part of a dedicated PhD fellowship scheme launched by EDCTP2 in 2020 to support women in health research across sub-Saharan Africa. Coordinated by the EDCTP Networks of Excellence, the initiative received funding from the UK National Institute for Health and Care Research (Department of Health and Social Care).
As part of her PhD requirements, Dr Mogashoa was expected to produce four manuscripts, with at least two accepted in peer-reviewed journals. She has exceeded this requirement, publishing three peer-reviewed articles from her doctoral work, with a fourth manuscript currently under review.
Her journey highlights the transformative impact of long-term investment in research training, mentorship, and gender equity. As she moves into the next phase of her career, her work promises to make a meaningful contribution to improving TB diagnosis, treatment, and control.
More information:
- Dr Tuelo Mogashoa Successfully Defends PhD in TB Genomics
- Tuelo’s journey: building Botswana’s capacity for cutting-edge health research
Prof. Novel Chegou Elected As Fellow Of The African Academy Of Sciences
Prof. Novel Chegou, EDCTP Senior Fellow and Acting Head of the Division of Immunology at the Faculty of Medicine and Health Sciences, Stellenbosch University, has been elected as a Fellow of the African Academy of Sciences. This important achievement recognises his scientific leadership and impactful research on tuberculosis, particularly his work on biomarkers to improve diagnosis and patient care in resource-limited settings.
Read more